Clarivate identifies fifteen potential blockbuster drugs in annual drugs to watch report

Report highlights personalized medicines ensuring greater efficacy for rare diseases and previously untreatable conditions promising therapeutic developments for hiv, parkinson's disease, crohn's disease, alopecia, multiple myeloma and breast cancer on horizon london , jan. 10, 2023 /prnewswire/ -- clarivate plc (nyse:clvt), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced the release of its annual drugs to watch™ report. in its 10th year, the drugs to watch report provides in-depth predictive analysis of drugs with the potential to transform treatment paradigms and serve unmet patient needs.
CLVT Ratings Summary
CLVT Quant Ranking